AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
1.980
-0.020 (-1.00%)
At close: Mar 28, 2025, 4:00 PM
1.960
-0.020 (-1.02%)
After-hours: Mar 28, 2025, 6:00 PM EDT
AC Immune Revenue
In the year 2024, AC Immune had annual revenue of 27.31M CHF with 84.51% growth. AC Immune had revenue of 1.14M in the quarter ending December 31, 2024, a decrease of -92.32%.
Revenue (ttm)
27.31M CHF
Revenue Growth
+84.51%
P/S Ratio
6.55
Revenue / Employee
158,773 CHF
Employees
172
Market Cap
195.91M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ACIU News
- 5 days ago - AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewsWire
- 17 days ago - AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 4 months ago - AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients - Benzinga
- 8 months ago - AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 - GlobeNewsWire
- 8 months ago - AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward - Seeking Alpha
- 8 months ago - AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease - GlobeNewsWire
- 10 months ago - AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 - GlobeNewsWire
- 11 months ago - Alzheimer's vaccine licensing deal boosts AC Immune - Market Watch